Celiprolol: Agonist and antagonist effects at cardiac β1- and vascular β2-adrenoceptors determined under in vivo conditions in the rat

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 6, 1997, Pages 689-698

  Alvarez Guerra, M ^a   Alda, O ^b   Garay, R P ^a  

^a INSERM   (France)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Blood pressure; Celiprolol; Rat; Adrenoceptor antagonists; Adrenoceptors

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CELIPROLOL; ISOPRENALINE; PROPRANOLOL; SALBUTAMOL; SYROSINGOPINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MALE; NONHUMAN; RAT;

EID: 0030824064     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005001     Document Type: Article

References (30)

1. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. BrJ Pharmacol 14: 48-58
2. Barrett J.A, Smith RD, Wolf PS, Pruss TP (1986) Beta-1 antagonist and cardiostimulatory effects of celiprolol in anesthetized dogs. Drug Dev Res 9: 159-169
3. Busst CM, Bush A (1989) Comparison of the cardiovascular and pulmonary effects of oral celiprolol, propranolol and placebo in normal volunteers. BrJ Pharmacol 27: 405-410
4. 2-adrenoceptor antagonists. Raven Press, New York, pp 31-42
5. Daul A, Wang XL, Borchard O, Block KD, Brodde OE (1986) Differential changes in lymphocyte beta-2 adrenoceptor density by beta-blocker administration: role of intrinsic sympathomimetic activity. J Cardiovasc Pharmacol 8[Suppl. 4]: S93-S96
6. De Mey C, Breithaupt-Grogler K, Schloos J, Palm D, Belz GG (1994) Reproducibility and consistency of the responses to supinal bicycle ergometry; evaluation in conjuction with beta 1-adrenoceptor occupancy. Br J Clin Pharmacol 38: 480-483.
7. Gomeri R, Gomeri G (1980) A conversational graphic program for the analysis of the sigmoid curve. Comput Biomed Res 13: 489-499
8. Heublein B, Modersohn D, Franz N, Panzer B (1991) Acute hæmodynamic profile of celiprolol in patients with coronary heart disease and hypertension : a double-blind comparison with metoprolol. Eur Heart J 12: 617-693
9. Hicks PE, Cavero I, Manoury P, Lefèvre-Borg F., Langer SZ (1987) Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Expl Ther 242: 1025-1034
10. Hoyer D, Boddeke HWGM (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14: 270-275
11. Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, Shankley NP (1995) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47: 255-266
12. Kirk RE (1968) Experimental design: procedures for behavioural sciences. Brooks/Cole Publishing Company, Belmont, California, pp 84-85
13. Louis WJ, Drummer OH, Tung LH (1990) Pharmacology of celiprolol. Cardiovasc Drugs Ther 4: 1281-1286
14. McLenachan JM, Grant S, Ford I, Henderson E, Dargie HJ (1991) Submaximal, but not maximal, exercise testing detects differences in the effects of beta-blockers during treadmill exercice: a study of celiprolol and atenolol. Am Heart J 121 (Part 2): 691-696
15. Michel MC, Wang XL, Daul A, Brodde OE (1987) Beta adrenoceptor antagonists with intrinsic sympathomimetic activity downregulate human lymphocyte beta-adrenoceptor density but do not activate the lymphocyte cyclic AMP system. J Cardiovasc Pharmacol 10 [Suppl. 10]: S117-S119
16. Milne RJ, Buckley MMT (1991) Celiprolol: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in cardiovascular disease. Drugs 41: 941-969
17. Miura K, Kimura Y, Inoue K, Matsuzaki T, Ochi S, Hamada S, Hugaski S, Tamura M, Kano S, Kimura K (1990) Pharmacological studies of celiprolol: 1. Beta-blocking effect, intrinsic sympathomimetic activity, vasodilating and hypotensive effects. Folia Pharmacol Jpn 95: 191-200
18. Neve KA, Barrett JA, Molinoff PB (1985) Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists. J Pharmacol Exp Ther 235: 657-664
19. Ochi S, Nakazawa M, Kimura T, Nagawa Y, Imai S (1991) Partial agonist activity of celiprolol, a cardioselective β-antagonist. EurJ Pharmacol 194: 1-5
20. Perrone MH, Barrett JA (1991) Preclinical pharmacology of celiprolol: a cardioselective ß-adrenergic antagonist and mild vasodilator. Am Heart J 121: 677-683
21. Pham-Huu-Chanh, De Schaepdryver AF (1965) On the pharmacology of syrosingopine and reserpine. Arch Int Pharmacodyn 157: 207-213
22. Pujet JC, Dubreuil C, Fleury B, Provendier O, Abella ML (1992) Effects ot celiprolol, a cardioselective beta-blocker, on respiratory function in asthmatic patients. Eur Respir J 5: 196-200
23. Reynolds EE, Molinoff PB (1986) Downregulation of beta-adrenergic receptors in S49 lymphoma cells induced by atypical agonists. J Pharmacol Expl Ther 234: 654-660
24. Saito T, Deguchi F, Iwata J, Yamamoto K, Inagaki Y (1993) Effects of celiprolol on hemodynamics during exercice loading and the responses caused by sympathomimetic drugs in essential hypertension. Curr Ther Res Clin Exp 4: 401-412
25. Silke B, Verma SP, Frais MA, Reynolds G, Taylor SH (1986) Comparative effecs of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercice-induced angina. Clin Pharmacol Ther 39: 5-14
26. Smith RD, Wolf PS (1984) Celiprolol. In: Scriabine A (ed) New drugs annual: cardiovascular drugs, vol 2, Raven Press, New York, pp 19-35
27. Smith RD, Cobuzzi A, Wolf PS, Pruss TP (1986) The antagonist and partial beta agonist properties of celiprolol in isolated rat cardiac tissues. Res Commun Chem Path Pharmacol 51: 147-160
28. Thulesius O, Gjores JE, Berlin E (1982) Vasodilaling properties of beta-adrenoceptor blockers with intrinsic sympathomimetic activity. Br J Clin Pharmacol 13: 2295-3305
29. Tolvanen JT, Wu X, Kähönen M, Sallinen K, Mäkynen H, Pekki A, Pörsti I (1996) Effect of celiprolol on arterial dilatation in experimental hypertension. Br J Pharmacol 119: 1137-1144
30. Tung LH, Jackman G, Campbell B, Louis S, Iakovidis D, Louis WJ (1993) Partial agonist activity of celiprolol. J Cardiovasc Pharmacol 21:484-488